Report Shows Benefits Of US Investment In Global Health R&D 03/08/2017 William New A new report from a global health advocacy group in Washington, DC shows the importance to the United States of US government investment in global health research and development and argues that more investment would have a tremendous positive impact on lives worldwide, including in fighting neglected diseases. Continue reading -> March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> US, EU Diverge On Medical Diagnostic Patents 10/05/2017 Kim Treanor A recent article in the journal Nature Biotechnology finds that since a key United States Supreme Court decision, the European Union and United States have diverged in their patent filings for medical diagnostics. Continue reading -> Posts navigation Newer posts
March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> US, EU Diverge On Medical Diagnostic Patents 10/05/2017 Kim Treanor A recent article in the journal Nature Biotechnology finds that since a key United States Supreme Court decision, the European Union and United States have diverged in their patent filings for medical diagnostics. Continue reading -> Posts navigation Newer posts
US, EU Diverge On Medical Diagnostic Patents 10/05/2017 Kim Treanor A recent article in the journal Nature Biotechnology finds that since a key United States Supreme Court decision, the European Union and United States have diverged in their patent filings for medical diagnostics. Continue reading -> Posts navigation Newer posts